Carboplatin dosing: gender bias and inaccurate estimates of glomerular filtration rate

被引：34
作者：
Dooley, MJ
Poole, SG
Rischin, D
Webster, LK
机构：
[1] Peter MacCallum Canc Inst, Pharmacol & Dev Therapeut Lab, Melbourne, Vic 3002, Australia
[2] Monash Univ, Victorian Coll Pharm, Dept Pharm Practice, Parkville, Vic 3052, Australia
[3] Peter MacCallum Canc Inst, Dept Haematol & Med Oncol, Melbourne, Vic 3002, Australia
来源：
EUROPEAN JOURNAL OF CANCER | 2002年 / 38卷 / 01期
关键词：
carboplatin; dosage; glomerular filtration rate; pharmacokinetics; Calvert formula; Chatelut formula; AUC;
D O I：
10.1016/S0959-8049(00)00455-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The aim as to compare doses of carboplatin calculated using the Calvert formula and Chatelut formula and also to compare doses calculated using Calvert formula, modified with non-isotopic estimation of GFR, using the Cockcroft and Gault formula or the Jelliffe formula. For formulae comparison. the doses were calculated to target an AUC of 7 mg ml.min. When compared with the dose derived from the Calvert formula, the doses calculated in 122 adult cancer patients using the Chatelut formula were significantly higher for males and significantly lower for females. There was a statistically significant difference between the dose per kg calculated for males and females (P < 0.0001). The mean percentage difference in dose calculated with substituted measures of renal function with the Cockcroft and Gault formula and Jelliffe formula was -8% (standard deviation (S.D.) 17%) and -14% (S.D. 16%). respectively. Further prospective evaluation of the Chatelut formula is required before it can be recommended for routine clinical application. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码：44 / 51
页数：8
相关论文
共 31 条
[21]   Carboplatin dosing based on measurement of renal function - Experience at the Peter MacCallum Cancer Institute [J].
Millward, MJ ;
Webster, LK ;
Toner, GC ;
Bishop, JF ;
Rischin, D ;
Stokes, KH ;
Johnston, VK ;
Hicks, R .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1996, 26 (03) :372-379
[22]  
Paccagnella A, 1996, CANCER, V78, P1701
[23]  
PETERS AM, 1991, EUR J NUCL MED, V18, P274, DOI 10.1007/BF00186653
[24]   SIMULTANEOUS MEASUREMENT OF RENAL CLEARANCE AND PLASMA-CLEARANCE OF TC-99M-LABELLED DIETHYLENETRIAMINEPENTA-ACETATE, CR-51-LABELED ETHYLENEDIAMINETETRA-ACETATE AND INULIN IN MAN [J].
REHLING, M ;
MOLLER, ML ;
THAMDRUP, B ;
LUND, JO ;
TRAPJENSEN, J .
CLINICAL SCIENCE, 1984, 66 (05) :613-619
[25]   IMPACT OF CYCLOPHOSPHAMIDE ON RELATIONSHIPS BETWEEN CARBOPLATIN EXPOSURE AND RESPONSE OR TOXICITY WHEN USED IN THE TREATMENT OF ADVANCED OVARIAN-CANCER [J].
REYNO, LM ;
EGORIN, MJ ;
CANETTA, RM ;
JODRELL, DI ;
SWENERTON, KD ;
PATER, JL ;
BURROUGHS, JN ;
NOVAK, MJ ;
SRIDHARA, R .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (06) :1156-1164
[26]  
RUSSELL CD, 1985, EUR J NUCL MED, V10, P519, DOI 10.1007/BF00252744
[27]   A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer [J].
Sculier, JP ;
Paesmans, M ;
Thiriaux, J ;
Lecomte, J ;
Bureau, G ;
Giner, V ;
Koumakis, G ;
Lafitte, JJ ;
Berchier, MC ;
Alexopoulos, CG ;
Zacharias, C ;
Mommen, P ;
Ninane, V ;
Klastersky, J .
EUROPEAN JOURNAL OF CANCER, 1999, 35 (09) :1314-1319
[28]   PHASE-I STUDY OF THE COMBINATION OF MONTHLY CARBOPLATIN AND WEEKLY CISPLATIN [J].
SESSA, C ;
GOLDHIRSCH, A ;
MARTINELLI, G ;
ALERCI, M ;
IMBURGIA, L ;
CAVALLI, F .
ANNALS OF ONCOLOGY, 1991, 2 (02) :123-129
[29]   LIMITATIONS OF CREATININE AS A FILTRATION MARKER IN GLOMERULOPATHIC PATIENTS [J].
SHEMESH, O ;
GOLBETZ, H ;
KRISS, JP ;
MYERS, BD .
KIDNEY INTERNATIONAL, 1985, 28 (05) :830-838
[30]  
vanWarmerdam LJC, 1996, CANCER CHEMOTH PHARM, V37, P266
1234